• Adam D Cohen, Ping Zhou, Joanne Chou, Julie Teruya-Feldstein, Lilian Reich, Hani Hassoun, Beth Levine, Daniel A Filippa, Elyn Riedel, Tarun Kewalramani, Michael D Stubblefield, Martin Fleisher, Stephen Nimer, and Raymond L Comenzo.
• Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. cohena@mskcc.org
• Br. J. Haematol. 2007 Oct 1; 139 (2): 224-33.

AbstractHigh-dose melphalan (MEL) with autologous stem cell transplant (SCT) is an effective therapy for systemic AL amyloidosis (AL), but treatment-related mortality (TRM) has historically been high. We performed a phase II trial of risk-adapted SCT followed by adjuvant dexamethasone (dex) and thalidomide (thal) in an attempt to reduce TRM and improve response rates. Patients (n = 45) with newly diagnosed AL involving < or =2 organ systems were assigned to MEL 100, 140, or 200 mg/m(2) with SCT, based on age, renal function and cardiac involvement. Patients with persistent clonal plasma cell disease 3 months post-SCT received 9 months of adjuvant thal/dex (or dex if there was a history of deep vein thrombosis or neuropathy). Organ involvement was kidney (67%), heart (24%), liver/GI (22%) and peripheral nervous system (18%), with 31% having two organs involved. TRM was 4.4%. Thirty-one patients began adjuvant therapy, with 16 (52%) completing 9 months of treatment and 13 (42%) achieving an improvement in haematological response. By intention-to-treat, overall haematological response rate was 71% (36% complete response), with 44% having organ responses. With a median follow-up of 31 months, 2-year survival was 84% (95% confidence interval: 73%, 94%). Risk-adapted SCT with adjuvant thal/dex is feasible and results in low TRM and high haematological and organ response rates in AL patients.

33 keywords...

hide…